SV Health Investors

SV Health Investors, established in 2005 and previously known as SV Life Sciences, is a prominent venture capital and growth equity firm based in the United States. The firm specializes in investments within the biotech and healthcare sectors, primarily focusing on North America and Western Europe. With over $2 billion in capital managed across seven private healthcare funds, SV Health Investors has built a strong reputation for supporting entrepreneurs who are developing innovative companies and transformative treatments. Boasting a 20-year track record, the firm operates from offices in Boston, San Francisco, and London, actively driving advancements in healthcare through strategic investments.

Alex Badamchi-Zadeh

Senior Associate

Michael H. Balmuth

Managing Partner

Kate Bingham

Managing Partner

Elizabeth Blake

Investment Associate

Hamish Cameron

Operating Partner

Elizabeth Campbell

Entrepreneur in Residence

Rebecca Canter

Associate

Michael G. Carter

Venture Partner

Bruce A. Cerullo

Operating Partner

Ailsa Craig

Investment Manager Public Equities UK

Lucy Costa Duarte

Head of Investor Relations Public Equities UK

Charles Dunn

Senior Associate

Brent Faduski

CFO

Thomas J. Flynn

Managing Partner

William Gerard

Analyst

Eugene D. Hill

Chairman

Carl Harald Janson

Investment Manager

Jack Kenney

Associate

Megan MacDonagh

Senior Associate

Greg Madden

Managing Partner

Niyoshi Patel

Associate

Marek Poszepczynski

Investor

Michael J. Ross

Managing Partner

Barbara Tate

Venture Partner Dementia USA

298 past transactions

Nimbus Apollo

Venture Round in 2022
Nimbus Apollo is a program under Nimbus Therapeutics that focuses on the development of innovative treatments for serious diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The program's lead candidate, NDI-010976, is an allosteric inhibitor of Acetyl-CoA Carboxylase (ACC), which has received Fast Track designation from the U.S. Food and Drug Administration. Nimbus Apollo is engaged in advancing this candidate through various stages of clinical development, with Phase 1 data expected to be presented at notable medical conferences. Nimbus Therapeutics, founded in 2009 and based in Cambridge, Massachusetts, leverages computational technology to design selective and potent small molecule therapeutics aimed at addressing metabolic diseases, cancer, and immune-inflammatory disorders. The company has established strategic partnerships to enhance its research and development efforts.

Ria Health

Series A in 2022
Ria Health is a telehealth provider focused on treating alcohol use disorders through a mobile platform. Founded in 2013 and based in San Francisco, California, the company connects users with addiction specialists for personalized support and guidance. Ria Health employs evidence-based protocols, including medication-assisted treatment, harm reduction, and cognitive behavioral therapy, to assist heavy drinkers seeking to reduce or stop their alcohol consumption. The Ria app facilitates secure, HIPAA-compliant interactions, allowing for video and phone consultations, breathalyzer measurements, and progress tracking. By offering a private and convenient treatment option, Ria Health aims to address the significant gap in care for individuals struggling with alcohol-related issues, ensuring effective and affordable support that aligns with payer objectives.

Rondo Therapeutics

Series A in 2022
Creating novel bispecific antibodies that activate the immune system to fight cancer

Eyebiotech

Series A in 2022
Eyebiotech is a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.

Perfuze

Series A in 2022
Perfuze develops technology to treat acute ischemic stroke. The company was founded in 2018 and is based in Galway, Ireland.

Quell Therapeutics

Series B in 2021
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Alpheus Medical

Series A in 2021
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

Zerigo Health

Series B in 2021
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

Eyebiotech

Seed Round in 2021
Eyebiotech is a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.

Artios Pharma

Series C in 2021
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Pulmocide

Series C in 2021
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Therini Bio

Seed Round in 2021
Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

Xilio Therapeutics

Series C in 2021
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

HPS / PayMedix

Acquisition in 2021
Health Payment Systems, Inc. is a healthcare company based in Milwaukee, Wisconsin, that specializes in simplifying the healthcare payment process for patients, providers, and employers. Founded in 2005, the company leverages electronic data exchange technology to process, consolidate, and transmit claims and payment information among stakeholders. HPS offers the Single Payment System, which enables hospitals and physicians to receive payments for both employers' and employees' portions of claims in a single electronic transaction. Additionally, the HPS SuperEOB provides a monthly billing statement that aggregates and clarifies various healthcare claims for individuals and families, enhancing transparency regarding costs and insurance coverage. HPS has formed a strategic alliance with Trilogy Health Networks to further its mission of improving the consumer experience in healthcare payments.

Leiters

Seed Round in 2020
Leiters Compounding Pharmacy, founded in 1925 and based in San Jose, California, is a FDA-registered 503B outsourcing provider specializing in high-quality ophthalmology and hospital-based pharmaceutical care. The company manufactures and sells a range of specialty compounding products, including ophthalmic solutions, autologous serums, and various sterile medications tailored for universities, hospitals, and health organizations across the United States. By leveraging a team of experts in sterile pharmaceutical manufacturing and utilizing state-of-the-art facilities, Leiters ensures the highest standards of quality and consistency in their products. They prioritize the well-being of patients, who have relied on Leiters for nearly a century. Customers can conveniently order products online, enhancing access to essential medications.

Catamaran Bio

Series A in 2020
Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

AavantiBio

Series A in 2020
AavantiBio, Inc. engages in developing gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. It focuses on Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company was incorporated in 2019 and is based in Gainesville, Florida.

Alchemab Therapeutics

Series A in 2020
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

Cellinta

Seed Round in 2020
Cellinta Limited is a biotechnology company focused on the research and development of gene therapies aimed at treating cancer. Founded in 2019 and headquartered in London, United Kingdom, Cellinta specializes in stem cell-based therapies to address brain cancers and other solid tumors. The company has created a platform that allows for the selective elimination of neural stem cells, utilizing computational tools and patient-derived cancer stem cell models. These innovations enable the identification of cancer stem cell-specific regulatory circuits, providing valuable insights and strategies for the medical community to combat cancer more effectively.

Evidation Health

Series D in 2020
Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors. It was founded in 2012 and is headquartered in San Mateo, California.

Amwell

Series C in 2020
Amwell is a telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 150 million lives. Amwell was founded in 2006 and is headquartered in Boston, Massachusetts.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Transposon Therapeutics

Seed Round in 2020
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseases

CytoMed Therapeutics

Venture Round in 2020
CytoMed Therapeutics is a cancer immunotherapy startup.

EBT Medical

Series A in 2019
EBT Medical, Inc. is a clinical-stage startup focused on developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly overactive bladder conditions. The company’s approach centers on the Saphenous nerve and is supported by scientific research originating from the University of Toronto. Founded in 2014 and headquartered in Boston, Massachusetts, with an additional office in Toronto, EBT Medical has emerged from a startup program that has successfully incubated numerous companies in the past decade. Through its pioneering therapies, EBT Medical seeks to address the needs of patients suffering from pelvic floor disorders.

Enara Bio

Series A in 2019
Ervaxx is pioneering the use of Dark Antigens™ to deliver targeted off-the-shelf cancer vaccines and other immunotherapies for treating and preventing cancer. Their Dark Antigens™ derive from vast untapped expanses of genetic ‘dark matter’ beyond the normal coding regions of the genome, which are generally silenced in normal tissue but are selectively activated in cancer.

Healthify

Series B in 2019
Healthify builds the infrastructure to support social determinants of health initiatives at scale. The company builds and manages accountable networks of community-based organizations and provides a technology platform that streamlines the closed-loop referral process, fosters collaboration across the network, and tracks results. Healthify works with community partners, health plans, and providers in all fifty states and is dedicated to community partner sustainability and demonstrating ROI for social service interventions to ensure that families receive the services they need to thrive.

Zerigo Health

Series A in 2019
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

AeroCare Direct

Private Equity Round in 2019
AeroCare Direct is a provider of home medical equipment based in Orlando, Florida, specializing in respiratory therapy services. The company offers a comprehensive range of products, including oxygen machines, CPAP and BiPAP devices, nebulizers, and various durable medical equipment designed for patients with chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), and Obstructive Sleep Apnea (OSA). AeroCare Direct enables patients to purchase CPAP and respiratory equipment directly, bypassing insurance complications that may arise due to costs or limitations on coverage. In addition to respiratory products, AeroCare also supplies a variety of daily living aids and medical supplies, ensuring that patients receive the necessary support for their health needs. The company operates a national network across the United States, emphasizing accessible care for individuals with breathing difficulties.

Bardy Diagnostics

Series B in 2019
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

CSA Medical

Venture Round in 2019
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.

myOrthos

Seed Round in 2019
Operator of an orthodontist support platform intended for orthodontists and supporting teams. The company's platform partners with orthodontists and provides them support like marketing, staff recruitment and training, office management, billing and collections, capital management, and succession planning, enabling practice partners to solve many practice transition challenges.

Caraway Therapeutics

Series A in 2018
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.

Ribometrix

Series A in 2018
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Urgent Team Holdings, Inc. operates urgent care centers that provide urgent and primary health care services. It offers services for patients in the areas of sprains, strains, and broken bones; muscular pain and injuries; eye irritation and eye injuries; cuts and scrapes; bites, stings, and allergic reactions; burns and infections; diarrhea, nausea, and vomiting; flu, colds, and viral illnesses; pneumonia and bronchitis; and asthma attacks. The company also offers preventative screenings/wellness services, including flu shots, physicals, immunization and vaccinations, EKGs, and osteoporosis screening, as well as blood glucose, blood pressure, and cholesterol checks; radiology, lab work and diagnostic testing, and drug and alcohol screening services; and services for employers.

Sitryx Therapeutics

Series A in 2018
Sitryx Therapeutics is a biopharmaceutical company established in 2018 and based in Oxford, United Kingdom. It focuses on developing disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. The company aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by renowned scientists from the United States and Europe, Sitryx has garnered significant funding, including a $30 million Series A round from various specialist investors. The company is actively engaged in multiple stages of drug discovery, working on a diverse pipeline of projects aimed at addressing unmet medical needs in immunometabolism.

Xilio Therapeutics

Series A in 2018
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Endotronix

Series D in 2018
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.

Bicycle Therapeutics

Series B in 2018
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Artios Pharma

Series B in 2018
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Evidation Health

Series C in 2018
Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors. It was founded in 2012 and is headquartered in San Mateo, California.

Sutro Biopharma

Series E in 2018
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Stimwave LLC

Venture Round in 2018
Stimwave LLC is a medical device company focused on developing, manufacturing, and marketing wireless microsize injectable devices for neurology applications. The company's product offerings include the Freedom SCS System, a spinal cord stimulator designed to alleviate chronic low back and leg pain, and the StimQ PNS System, a peripheral nerve stimulator that addresses chronic pain by targeting specific peripheral nerves. Originally incorporated as Neural Micro Incorporated in 2010, Stimwave LLC is headquartered in Pompano Beach, Florida.

Centauri Health Solutions

Venture Round in 2018
Centauri Health Solutions is a technology-centric company specializing in hosted software solutions, data-driven services, and data management designed specifically for risk adjustment and quality based revenue programs.

Avrobio

Series B in 2018
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

LOQUS23 THERAPEUTICS

Seed Round in 2018
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Pionyr Immunotherapeutics

Series B in 2017
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.

Misonix

Post in 2017
Misonix has long been at the forefront of ultrasound technology and is a world leader in the design, development, manufacturing, and marketing of ultrasonic surgical devices. Their innovative, ultrasonic platforms for surgical applications include aspirators for the removal of both soft and hard tissue, instruments for laparoscopic cutting and coagulation, devices for wound cleansing and debridement, products for precision bone cutting and sculpting, liposuction instrumentation for improving body aesthetics, and High Intensity Focused Ultrasound (HIFU) systems for the ablation of tumors.

Ribometrix

Seed Round in 2017
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

PanOptica

Series B in 2017
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.

Cerevance

Series A in 2017
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Arsanis

Series D in 2017
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Pulmocide

Series B in 2017
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Bardy Diagnostics

Series A in 2017
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

Pionyr Immunotherapeutics

Series A in 2017
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.

Good Start Genetics

Debt Financing in 2016
Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

NKT Therapeutics

Venture Round in 2016
NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of therapeutics that harness the unique properties of natural killer T (NKT) cells. Incorporated in 2008, the company aims to create a pipeline of innovative NKT-based treatments targeting a range of conditions, including cancer, sickle cell disease, autoimmune disorders, inflammatory diseases, infectious diseases, asthma, and dermatitis. Through its focused research and development efforts, NKT Therapeutics strives to advance first-in-class therapies that can address unmet medical needs in these areas.

CardioKinetix

Series F in 2016
CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.

CSA Medical

Debt Financing in 2016
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.

SUN Behavioral Health

Series A in 2016
SUN Behavioral Health, Inc. operates hospitals that provide various behavioral health services to children, youth, adults, and seniors. The company’s services include inpatient psychiatric and substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. It also serves women, and active duty and veteran military persons. The company is based in Red Bank, New Jersey. SUN Behavioral Health, Inc. operates as a subsidiary of SUN Behavioral HoldCo, LLC.

Cibiem Inc.

Debt Financing in 2016
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.

ValenTx

Debt Financing in 2016
ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, that specializes in developing therapy solutions for obesity and related metabolic disorders. The company offers an endoluminal bypass therapy, which replicates the effects of the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's solutions primarily target conditions such as type-2 diabetes and hypertension. Founded in 2002, the company is committed to advancing minimally-invasive treatments for morbid obesity.

Maestro Health

Series A in 2016
Founded in 2013, Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.

Bicycle Therapeutics

Series A in 2016
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Artios Pharma

Series A in 2016
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

AcuFocus

Private Equity Round in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Artios Pharma

Seed Round in 2016
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Kesios Therapeutics

Debt Financing in 2016
Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma The NF-κB Pathway and Novel Oncology Target (GADD45β/MKK7), Research and Development pipeline and related indications. The company was incorporated in 2012 and is based in Cambridge, United Kingdom.

Avrobio

Series A in 2016
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

SUN Behavioral Health

Series A in 2016
SUN Behavioral Health, Inc. operates hospitals that provide various behavioral health services to children, youth, adults, and seniors. The company’s services include inpatient psychiatric and substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. It also serves women, and active duty and veteran military persons. The company is based in Red Bank, New Jersey. SUN Behavioral Health, Inc. operates as a subsidiary of SUN Behavioral HoldCo, LLC.

Aligned TeleHealth

Series A in 2016
Aligned Telehealth is a provider of a SaaS-based platform used to offer telemedicine and healthcare management services. Its platform offers full, end-to-end telemedicine services, including psychiatric specialty physician consultations to acute-care hospitals, emergency rooms, skilled nursing facilities, and correctional institutions that enable clients to deliver improved quality and efficient patient care.

Good Start Genetics

Debt Financing in 2016
Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Halscion, Inc.

Debt Financing in 2016
Halscion, Inc. specializes in the development of innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company's flagship product is a single-use hydrogel scaffold that is injected during surgical procedures at the dermal-subdermal interface of wounds. This device facilitates the migration of the patient’s own cells, such as fibroblasts, into the wound in a structured manner, promoting more effective healing. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

Direct Flow Medical

Venture Round in 2016
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

Endotronix

Series C in 2016
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.

PanOptica

Series B in 2016
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.

AcuFocus

Debt Financing in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Karus Therapeutics

Series B in 2016
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of innovative medicines for cancer. Established in 2005, the company focuses on designing and developing orally-active small molecule drugs aimed at targeting specific molecular pathways. Its notable products include KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, designed for treating both hematological and solid tumors, and KA2507, an HDAC6 inhibitor intended for tumors expressing PD-L1. Karus Therapeutics aims to address unmet medical needs in oncology through its targeted therapeutic approaches.

Arsanis

Series C in 2016
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Jet Health

Series A in 2016
JET Health Solutions is a healthcare technology company focused on providing smart solutions for healthcare payers across the country. Our flagship product, JET Insure, is a quote-to-card (Q2C) insurance automation platform that provides individual/family plans, group plans, stop-loss/self-funded options, and specialty products on a single, cloud-based solution.

TopiVert

Series A in 2016
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.

VHSquared

Series A in 2016
VHsquared Ltd. develops oral biologics for immuno-inflammatory targets in the gastro intestinal tract. The company identifies, screens, selects, and engineers Vorabodies, a transformational therapy for the treatment of inflammatory bowel disease. It uses its Vorabody platform to generate potent protease resistant domain antibodies for oral administration. The company was incorporated in 2010 and is based in Cambridge, United Kingdom.

Arsanis

Debt Financing in 2016
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

AeroCare Direct

Series A in 2016
AeroCare Direct is a provider of home medical equipment based in Orlando, Florida, specializing in respiratory therapy services. The company offers a comprehensive range of products, including oxygen machines, CPAP and BiPAP devices, nebulizers, and various durable medical equipment designed for patients with chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), and Obstructive Sleep Apnea (OSA). AeroCare Direct enables patients to purchase CPAP and respiratory equipment directly, bypassing insurance complications that may arise due to costs or limitations on coverage. In addition to respiratory products, AeroCare also supplies a variety of daily living aids and medical supplies, ensuring that patients receive the necessary support for their health needs. The company operates a national network across the United States, emphasizing accessible care for individuals with breathing difficulties.

Good Start Genetics

Debt Financing in 2016
Good Start Genetics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is a molecular diagnostics company specializing in genetic screening for inherited diseases. The company aims to transform reproductive medicine by offering clinically relevant information to physicians and patients regarding genetic disorders. Its flagship product, EmbryVu, is a preimplantation genetic screening test designed to enhance in vitro fertilization by identifying suitable embryos for implantation and pregnancy. Good Start Genetics employs advanced next-generation DNA sequencing (NGS) technology, alongside other established genetic screening methods, to provide a comprehensive suite of genetic carrier screening tests through its GoodStart Select program. The company emphasizes customer care and genetic counseling, ensuring that patients receive actionable insights into known and novel genetic mutations. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Soffio Medical

Series A in 2016
Soffio Medical is a medical company that develops medical apparatus for respiratory diseases. The company is based in Boston, Massachusetts.

AcuFocus

Debt Financing in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Bicycle Therapeutics

Series A in 2016
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Cibiem Inc.

Series B in 2016
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.

Maestro Health

Series A in 2016
Founded in 2013, Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.

Delenex Therapeutics

Venture Round in 2016
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

AcuFocus

Debt Financing in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.

Thesan Pharmaceuticals

Series B in 2016
Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Until recently, there has been comparatively limited innovation in the field of dermatology, where many companies have focused on the reformulation of existing drugs often resulting in marginal patient benefit. In contrast, Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.

PanOptica

Series B in 2016
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.